航新科技(300424.SZ):已完成兑付相關商業票據
格隆匯5月10日丨航新科技(300424.SZ)公佈,2022年5月7日上海票據交易所披露了《持續逾期名單(截至2022年4月30日)》,即2021年11月1日至2022年4月30日出現3次以上付款逾期,且截至2022年4月30日有逾期餘額或2022年4月當月出現付款逾期的承兑人名單。公司被列入上述名單。
經核實,2022年1月1日至4月30日,公司共有15筆商業承兑匯票兑付構成逾期,累計發生金額829.09萬元。截公吿披露之日,相關商業票據已在持票人提示付款申請後完成兑付。
經核查,由於春節期間放假安排以及具體經辦人員工作疏忽、業務能力有待提升等原因造成公司未及時兑付相關商業承兑匯票。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.